Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT06649331Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Oct 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan, tizetatug rezetecan, ruzaltatug rezetecan, SHR-A2102, bulumtatug fuvedotin in breast cancer, sponsored by Fudan University. Started Oct 2024; status: recruiting.
02
Drugs
trastuzumab rezetecantizetatug rezetecanruzaltatug rezetecanSHR-A2102bulumtatug fuvedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06649331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649331.